The new patent will extend coverage to include a significantly broader gamut of chemical compounds, which the company might develop as immune-modulating drugs targeting an inflammatory pathway involved
Under the deal, Yabao secured exclusive rights to develop and commercialize LS-008 in China while Le Sun retains majority of exclusive rights in all other markets. Both the
The contract includes performing studies on the vaccine that has been licensed from the Public Health Agency of Canada, to move it closer to human clinical trials. The
Currently, the company is developing TRV734 to optimize analgesia while reducing on-target gastrointestinal and central nervous system adverse effects through its new biased ligand mechanism at the mu-opioid
The approval in the European Union (EU) was based on results of the Phase III Aurelia trial which included women with recurrent, platinum-resistant ovarian cancer who received either
Sivextro is a short, six-day course therapy for the treatment of serious skin infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The drug was approved by the
Polycythemia vera is a form of blood cancer that leads to the overproduction of normal red blood cells, white blood cells and platelets. The filing of the sNDA
The company said that an epilepsy medication is a natural extension to its product line. The prevalence of migraine in people who experience epilepsy is 8.4 to 20%,
In the European Union (EU), defibrotide is marketed by Jazz Pharmaceuticals under the name Defitelio for the treatment of severe hepatic veno-occlusive disease (VOD) in patients over one
The company said that oral pirfenidone (Esbriet) has shown promise to slow IPF disease progression and a very large oral dose is required to achieve efficacious lung levels.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.